Intensity Therapeutics granted Nasdaq listing extension until June 1, 2026.

viernes, 5 de diciembre de 2025, 7:35 am ET1 min de lectura
INTS--

Intensity Therapeutics has been granted a 180-day extension by Nasdaq to regain compliance with the minimum $1.00 bid price requirement for continued listing. The company now has until June 1, 2026, to meet the requirement. Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios